{
  "ticker": "LLY",
  "target_date": "2025-03-27",
  "actual_date": "2025-03-27",
  "collected_at": "2025-12-08T11:34:14.451556",
  "price": {
    "open": 818.14,
    "high": 822.06,
    "low": 810.65,
    "close": 816.9923095703125,
    "volume": 2128200,
    "change_1d_pct": -0.62,
    "change_7d_pct": -0.1,
    "change_30d_pct": -5.71
  },
  "technicals": {
    "rsi_14": 37.32,
    "sma_20": 849.85,
    "sma_50": 835.61,
    "macd": -6.184,
    "macd_signal": -3.345,
    "macd_histogram": -2.839,
    "bb_upper": 934.21,
    "bb_lower": 765.49,
    "price_vs_sma20_pct": -3.87,
    "price_vs_sma50_pct": -2.23,
    "volume_ratio": 0.59
  },
  "fundamentals": {
    "market_cap": 888836915200,
    "pe_ratio": 48.57913,
    "forward_pe": 43.755516,
    "price_to_book": 37.330574,
    "price_to_sales": 14.958598,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.84,
    "pct_from_52w_low": 58.95
  },
  "macro": {
    "spy": {
      "price": 563.85,
      "change_1d_pct": -0.27,
      "change_7d_pct": 0.29
    },
    "vix": {
      "level": 18.69,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.37
    },
    "dollar_index": {
      "level": 104.07
    },
    "gold": {
      "price": 3060.2
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update",
      "source": "SeekingAlpha",
      "datetime": 1743108470,
      "summary": "AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",
      "url": "https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c"
    },
    {
      "headline": "VIG: Index Rebalance Adds Eli Lilly To Bolster Dividend Growth In 2025",
      "source": "SeekingAlpha",
      "datetime": 1743107997,
      "summary": "VIG's recent rebalancing impacts its holdings, yield, and dividend growth streak. Read here for a comparison with SPY, DGRO, and DGRW ETFs.",
      "url": "https://finnhub.io/api/news?id=e51b13f6428a2a7cd526321e069d59dbfb99688748f82c2b210d4b938684310b"
    },
    {
      "headline": "Eli Lilly and Company (LLY): Among Dividend Zombies to Invest in",
      "source": "Yahoo",
      "datetime": 1743105017,
      "summary": "We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to invest in. The broader market has posted consecutive annual gains of 25%, largely fueled by growth stocks ",
      "url": "https://finnhub.io/api/news?id=e239504768bcee0a66f6617d723f5a8906e58a4b90f6f846fa0dcb0664f47945"
    },
    {
      "headline": "Novo shares on track for biggest monthly fall since 2002, investor worries grow",
      "source": "Yahoo",
      "datetime": 1743096558,
      "summary": "LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. rival Eli Lilly.  Novo came under pressure last year to prove it could",
      "url": "https://finnhub.io/api/news?id=b57aa6a99b264d7b48fccf7f96f99f9b99c44aa4ea44b8bd35d3f90706a4065e"
    },
    {
      "headline": "Eli Lilly (NYSE:LLY) Expands Digital Platform For Alzheimer's Care As Shares Stay Flat",
      "source": "Yahoo",
      "datetime": 1743096436,
      "summary": "Eli Lilly (NYSE:LLY) announced an expansion of its LillyDirect digital healthcare platform to facilitate contact with healthcare providers for Alzheimer's patients\u2014providing a targeted solution for timely diagnosis amid highlighted capacity issues. This aligns with a broader push in addressing Alzhe",
      "url": "https://finnhub.io/api/news?id=974b0a42f74b5eee837f5fab81ac0121f8ccd98df9aa4b184bbbabc3ab2efae5"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}